-
Article
Open AccessL-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II tri...
-
Article
Open AccessDecision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany
The decision-making process regarding cancer treatment is emotionally challenging for patients and families, harboring the risk of decision regret. We aimed to explore prevalence and determinants of decision r...
-
Article
Open AccessCDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data
Homozygous CDKN2A/B deletion has been associated with an increased risk of recurrence in meningiomas. However, the evidence is confined to a limited number of studies, and the importance of heterozygous CDKN2A...
-
Article
Open AccessCorrection to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
-
Article
Open AccessThe proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
The AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate thes...
-
Article
Open AccessUndetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses
In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma. Progression-free survival (PFS) and...
-
Article
Open AccessLong-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up
Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients’ neurocognition and quality of life. The prese...
-
Article
Open AccessPrognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS
The role of obesity in glioblastoma remains unclear, as previous analyses have reported contradicting results. Here, we evaluate the prognostic impact of obesity in two trial populations; CeTeG/NOA-09 (n = 129...
-
Article
Open AccessPhase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
Glioblastoma is the most frequent and malignant primary brain tumor. Even in the subgroup with O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and favorable response to first-line therapy, ...
-
Article
Open AccessCorrection to: Innovative radiation oncology Together—Precise, Personalized, Human
-
Article
Open AccessInnovative radiation oncology Together – Precise, Personalized, Human
Scientific and clinical achievements in radiation, medical, and surgical oncology are changing the landscape of interdisciplinary oncology. The German Society for Radiation Oncology (DEGRO) working group of yo...
-
Living Reference Work Entry In depth
Kindliche Hirntumoren bei Erwachsenen: Pinealistumoren
Nach der aktuellen WHO-Klassifikation werden Pineozytome (WHO-Grad I), pineale parenchymale Tumoren intermediärer Differenzierung (PPID, WHO-Grad II, III), Pineoblastome (WHO-Grad IV) und papilläre Tumoren der...
-
Living Reference Work Entry In depth
Kindliche Hirntumoren bei Erwachsenen: Tumoren der Sella
Kraniopharyngeome sind seltene Tumoren mit einer Prävalenz von 0,5–2,5 Erkrankten. Adamantinöse Kraniopharyngeome treten bei Kindern und im mittleren Erwachsenenalter auf, papilläre Kraniopharyngeome ausschlie...
-
Living Reference Work Entry In depth
Kindliche Hirntumoren bei Erwachsenen: Medulloblastom
Medulloblastome gehören bei Kindern mit zu den häufigsten Tumoren, bei Erwachsenen sind sie selten. Das Altersmaximum liegt bei 5 Jahren. Nach der aktuellen WHO Klassifikation werden vier histologischen Subgru...
-
Article
Open AccessNeurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study
Combined radiochemotherapy followed by maintenance chemotherapy with cisplatin, lomustine and vincristine within the NOA-07 study resulted in considerable short-term toxicity in adult medulloblastoma patients....
-
Living Reference Work Entry In depth
Radiation Therapy in Ependymal Tumors
Ependymoma are rare malignant CNS tumors of the WHO grades I–III in children and adults with a tendency to spread within in the CSF. Several genetic subtypes with different clinical behaviors have been discove...
-
Article
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial
The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozol...
-
Article
Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen
As the efficacy of all pediatric high-grade glioma (HGG) treatments is similar and still disappointing, it is essential to also investigate the toxicity of available treatments.
-
Article
White matter lesions reduce number of brain metastases in different cancers: a high-resolution MRI study
Brain metastases are major complications of common cancers. Tumor type and proneness to the CNS are thought to define the number and size of brain metastases. It is not known if intrinsic vascular factors can ...
-
Article
Comment on: Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?
